First-line maintenance therapy with Ninlaro (ixazomib) significantly delays disease progression or death in adults with multiple myeloma who had not been initially treated with an autologous stem cell transplant (ASCT), according to data from a Phase 3 trial. “There is a strong need for additional maintenance treatments for multiple myeloma, where currently approved options are limited,” Meletios Dimopoulos, MD, the trial’s principal investigator, and a professor and chairman of the department of clinical therapeutics at the University…
You must be logged in to read/download the full post.
The post Ninlaro Maintenance Therapy Improves Survival in Patients Not Given ASCT, Trial Shows appeared first on BioNewsFeeds.